MAP2K7 and breast cancer: Ishay-Ronen et al.3 have reported that combinatorial treatment with MEK inhibitors and the antidiabetic drug rosiglitazone induces the conversion of invasive and metastatic breast cancer cells into adipocytes, thereby repressing primary tumor cell invasion and metastasis in breast cancer.